Health Canada Approves Subcutaneous Infliximab Biosimilar The infliximab biosimilar CT-P13, developed by Celltrion and marketed as Remsima has been approved by HealthCanad for subcutaneous (SC) use in all the indications for infliximab. https://t.co/7pS7y4sys9